Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen
Executive Summary
Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.